Abstract: Objective To find out about the clinical characteristics of Xiyanping injection in the treatment of bacterial intestinal infections in order to provide reference for its clinical use. Methods A total of 3 846 patients with bacterial intestinal infections treated with Xiyanping injection were selected from clinical information systems of 14 big hospitals in China between July 26, 2011 and June 1, 2019. The records of clinical medications, diagnostic protocols, basic data on treatment and combined medications were analyzed using frequency statistics and association rules. Results Most of the patients were aged 1 to 3 (2 378 cases). Male patients outnumbered female ones. The top three comorbidities included other forms of heart disease, acute upper respiratory tract infections and metabolic disease. In terms of drug combinations, the main Western drugs were those for other forms of heart disease, heparin drugs, third-generation cephalosporins, mucolytic drugs and H2-receptor antagonists. Drug combinations with traditional Chinese medicine were dominated by heat-clearing agents. The third-generation cephalosporin and penicillin were the most common Western drugs combined with antibiotics. Conclusion Patients with bacterial intestinal infections may also be complicated with or vulnerable to secondary cardiac diseases and acute upper respiratory tract infections. It is critical to find out whether patients have such diseases. At the same time, clinicians should be alert to adverse reactions caused by Xiyanping injection when used in combination with other drugs.

Key words: real world, Xiyanping, injection, bacterial intestinal infection, drug characteristics